TY  - JOUR
T1  - Bloodstream Infections in Solid Tumor Malignancy: Risk Factors and Clinical Outcome
A1  - Ann Gie Ong
A1  - Endang Kumolosasi
A1  - Farida Islahudin
A1  - Si Yan Chan
A1  - Xin Yi Lim
A1  - Suhaila Md Hanapiah
A1  - Azmi Nor Mohd Farez Ahmat
JF  - Archives of Pharmacy Practice
JO  - Arch Pharm Pract
SN  - 2320-5210
Y1  - 2021
VL  - 12
IS  - 3
DO  - 10.51847/1HP2oqD3ZK
SP  - 34
EP  - 40
N2  - Bloodstream infection (BSI) is a common complication in patients with solid tumor malignancies but available information on risk factors associated with BSI among these patients is scarce. To determine the associated risk factors and clinical outcomes of antibiotic treatment in BSI solid tumor malignancies. This was a retrospective case-control study performed in the National Care Centre. Adult patients with solid tumor malignancy and positive for blood culture bacteria growth (n=130) as well as adult patients with solid tumor malignancy and negative for blood culture bacteria growth were included (n=130). The most common form of solid malignancy (n=260) are those associated with digestive organs (n=72, 27.7%) and breast tumors (n=57, 21.9%). From 130 patients that were positive for BSI, gram-negative infection occurred in 71.5% (n=93) of the cases, mainly due to Klebsiella pneumoniae (n=31, 21.5%), Escherichia coli (n=24, 16.7%), and Pseudomonas aeruginosa (n=17, 11.8%). 98.2% (n=128) of BSI patients received empirical antimicrobial therapy while 58.5% (n=76) received adequate empirical antibiotic coverage. Elevated CRP levels (Adjusted OR=1.009; 95%CI=1.003–1.015; p=0.002) and total lymphocyte counts of 
UR  - https://archivepp.com/article/bloodstream-infections-in-solid-tumor-malignancy-risk-factors-and-clinical-outcome-c2bg72ydwqm68ad
ER  -